Ascletis Reports Strong Phase II Data for Hepatitis C Drug

Ascletis, a US-China pharma, reported that one of its two potential treatments for hepatitis C, ASC08, a direct acting antiviral agent that Ascletis in-licensed from Roche, produced positive results in a Phase II trial. The trial enrolled Taiwanese patients. After 12 weeks of treatment, the SVR12 (sustained viral response) rate observed in genotype 1 non-cirrhotic Taiwanese patients was 94% and 100% in genotype 1b non-cirrhotic Taiwanese patients. Ascletis pointed out that Genotype 1b accounts for 98% of genotype 1 and 57% of all hepatitis C patients in mainland China. More details.... Stock Symbol: (SIX: ROG) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.